ライフサイエンスコーパス: ranitidine

1 re on standard acid-suppressive therapy with ranitidine.

2 rmation yield of NDMA from chloramination of ranitidine.

3 e decomposition of the methylfuran moiety of ranitidine.

4 re chlorinated and hydroxylated analogues of ranitidine.

5 acid and 20 animals fed pH 7 formula without ranitidine.

6 e, and group 2 patients received intravenous ranitidine.

7 nytoin or carbamazepine), dexamethasone, and ranitidine.

8 Sucralfate was given to 47, and 49 received ranitidine.

9 d quinidine, drugs structurally unrelated to ranitidine.

10 mpromise or transfusion); all were receiving ranitidine.

11 e, patients received an intravenous bolus of ranitidine (0.5 mg/kg) followed by a continuous infusion

12 to BK induced by histamine was inhibited by ranitidine (10 microM).

13 with omeprazole at bedtime (P = NS); 4 with ranitidine, 150 mg at bedtime; and 3 with ranitidine, 30

14 time: placebo; additional omeprazole, 20 mg; ranitidine, 150 mg; and ranitidine, 300 mg.

15 through chloramination of the pharmaceutical ranitidine (3 muM).

16 d, placebo-controlled, double-blind trial of ranitidine 300 mg (orally twice daily) in subjects with

17 th ranitidine, 150 mg at bedtime; and 3 with ranitidine, 300 mg at bedtime (P < 0.05, ranitidine vs.

18 l omeprazole, 20 mg; ranitidine, 150 mg; and ranitidine, 300 mg.

19 The most commonly used agents for SUP were ranitidine (31%), famotidine (24%), sucralfate (24%), an

20 ell+/-SEM are reported: control 68.3+/-37.8; ranitidine 38.4 +/-94.2; lansoprazole 14.6+/-84.4; and o

21 nes that produce NDMA at high yields, namely ranitidine, 5-(dimethylaminomethyl)furfuryl alcohol, N,N

22 ated premedication regimen that consisted of ranitidine 50 mg, diphenhydramine 50 mg, and a single 20

23 razole (0.35 microg/mL); and d) control plus ranitidine (50 microg/mL).

24 etics of decomposition of the pharmaceutical ranitidine (a major precursor of NDMA) during chloramina

25 stric pH should be monitored and the dose of ranitidine adjusted accordingly.

26 , and the H2 histaminergic receptor agonist, ranitidine, also hindered recognition of the familiar ju

27 nd the H2 histaminergic receptor antagonist, ranitidine, also hindered the recognition of the familia

28 animals, either alone or in combination with ranitidine (an alcohol dehydrogenase inhibitor) while th

29 ncluding histamine H(2) receptor antagonist (ranitidine), analgesic (paracetamol), opiate (codeine),

30 Complete removal of ranitidine and cimetidine was achieved within 30 min of

31 The H(2) antagonists, ranitidine and famotidine, exhibit saturable absorptive

32 hloramine, nucleophilic substitution between ranitidine and monochloramine led to byproducts that are

33 Ranitidine and tetrodotoxin abolished the inhibitory eff

34 ed with a minimum 3 mg/kg/day of intravenous ranitidine and the dose should be titrated to a gastric

35 gonists such as diphenhydramine, loratadine, ranitidine, and cimetidine, but has modest affinity for

36 fter exposure to the H2 receptor antagonist, ranitidine, and identified an antibody that reacted with

37 Continuous infusion of ranitidine at 6.25 mg/hr (n = 9) or placebo (n = 11) for

38 omeprazole at bedtime with that of a dose of ranitidine at bedtime on residual nocturnal acid secreti

39 Ranitidine at bedtime reduced this parameter more, 5% wi

40 Regimen 2, ranitidine-bismuth-citrate + clarithromycin, was support

41 niramine, but not the H2 receptor antagonist ranitidine, blocks the effects of histamine in this prep

42 fect of the histamine-2-receptor antagonist, ranitidine, both at the cellular and mediator levels in

43 269 pg/mL (p < .05) in patients treated with ranitidine, but not in patients treated with placebo.

44 Treatment with ranitidine, but not placebo, was associated with a signi

45 Ranitidine caused increased DNA synthesis in PBMCs when

46 Oxidation of ranitidine, cimetidine, and ciprofloxacin was primarily

47 e continuous infusion, the mean steady-state ranitidine concentration associated with gastric pH > or

48 he American population would need to consume ranitidine daily to match the NDMA loadings from laundry

49 antihistamine treatments with pyrilamine or ranitidine did not impair tolerance and neither did IgE-

50 in this study may used to design an initial ranitidine dosage regimen that targets a gastric pH > or

51 The minimum ranitidine dose recommended in commonly used pediatric d

52 Gastric pH was determined at the end of the ranitidine dosing interval, 1 hr after the dose, and at

53 orothiazide (during the whole treatment) and ranitidine-fenofibrate (at short periods) in the BTV bio

54 The reaction between monochloramine and ranitidine followed second order kinetics and was acid-c

55 Most respondents selected ranitidine for ease of administration, famotidine becaus

56 24 hrs of scheduled intermittent intravenous ranitidine for stress ulcer prophylaxis were enrolled in

57 Decomposition of ranitidine formed different byproducts depending on the

58 In the ranitidine group, there were no significant elevations i

59 In both the sucralfate and ranitidine groups, clinical characteristics, number of d

60 cetate production by as much as 59%, whereas ranitidine had no significant effect.

61 ent of patients who received <3 mg/kg/day of ranitidine had poor gastric pH control as compared with

62 Ranitidine hydrochloride at 20 mg x kg(-1) x day(-1) was

63 patients, after treatment with cisapride or ranitidine in 2 patients, and after Nissen fundoplicatio

64 The pharmacokinetics of ranitidine in critically ill children are variable.

65 Cimetidine, but not ranitidine, inhibits gastric alcohol metabolism in keepi

66 Bedtime ranitidine is more effective than bedtime omeprazole on

67 servation implies that the N(CH3)2-moiety of ranitidine is transferred to NDMA without being chemical

68 the delta(2)H value of the N(CH3)2-group of ranitidine measured by quantitative deuterium nuclear ma

69 line or an antisecretory dose of omeprazole, ranitidine, or cimetidine, were intragastrically adminis

70 nificant difference between lansoprazole vs. ranitidine (p< .01), and omeprazole vs. ranitidine (p< .

71 vs. ranitidine (p< .01), and omeprazole vs. ranitidine (p< .05), and no significant difference betwe

72 Ranitidine pharmacokinetics were determined after a sing

73 sess the impact of multiple risk factors and ranitidine prophylaxis on the development of stress-rela

74 doses of the histamine 2-receptor antagonist ranitidine (RAN) and bacterial lipopolysaccharide (LPS)

75 of the tertiary amines, mianserin (MIA) and ranitidine (RAN), exhibiting similar compound specificit

76 yrilamine) and H3 (thioperamide) but not H2 (ranitidine) receptor antagonists at 10 microM.

77 els were significantly lower in placebo than ranitidine recipients.

78 cokinetic variables, the dose of intravenous ranitidine required to target 373 ng/mL as the average s

79 1 and 2 receptor antagonists pyrilamine and ranitidine, respectively, did not significantly alter NT

80 The description of ranitidine's pharmacokinetics and pharmacodynamics in th

81 These results indicate that ranitidine should be avoided where possible in the proph

82 Ranitidine should not be recommended for the treatment o

83 ly the parietal cell signal was inhibited by ranitidine, showing the absence of PAC1 on parietal cell

84 onsumption of a standard dose of the antacid ranitidine substantially increased NDMA and its chlorami

85 The probe irreversibly inhibited ranitidine transport across Caco-2 cell monolayers and i

86 Infectious complications totaled 128 in the ranitidine-treated group and 50 in the sucralfate-treate

87 of infectious complications associated with ranitidine use and total infectious complications were a

88 Ranitidine use in severely injured patients is associate

89 Ranitidine use was associated with a 1.5-fold increased

90 ith ranitidine, 300 mg at bedtime (P < 0.05, ranitidine vs. placebo).

91 Gastric pH control with ranitidine was considered unsuccessful (poorly controlle

92 Of the drugs studied, ranitidine was used most often (15,627 neonates, 35 expo

93 The oral antihistamines pyrilamine and ranitidine were administered during tolerance induction

94 nts enrolled in a randomized trial comparing ranitidine with sucralfate for gastritis prophylaxis wer